NEW YORK(GenomeWeb) – BG Medicine said today that it has been granted continued listing on the Nasdaq Capital Market while it works towards compliance with exchange listing requirements.

In November, the company was told that it did not meet the minimum of $2.5 million in stockholders' equity or a market capitalization of at least $35 million required for listing, putting the company at risk of being delisted.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.